CN115918730A - Formula and production process of goat milk powder with immunity enhancing function - Google Patents
Formula and production process of goat milk powder with immunity enhancing function Download PDFInfo
- Publication number
- CN115918730A CN115918730A CN202211394186.4A CN202211394186A CN115918730A CN 115918730 A CN115918730 A CN 115918730A CN 202211394186 A CN202211394186 A CN 202211394186A CN 115918730 A CN115918730 A CN 115918730A
- Authority
- CN
- China
- Prior art keywords
- goat milk
- milk powder
- powder
- freeze
- dried powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 97
- 235000020251 goat milk Nutrition 0.000 title claims abstract description 86
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 32
- 230000036039 immunity Effects 0.000 title claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 238000009472 formulation Methods 0.000 title description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract description 29
- 239000000832 lactitol Substances 0.000 claims abstract description 29
- 229960003451 lactitol Drugs 0.000 claims abstract description 29
- 235000010448 lactitol Nutrition 0.000 claims abstract description 29
- 229920001202 Inulin Polymers 0.000 claims abstract description 22
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 22
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 22
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 22
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 22
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 22
- 229940029339 inulin Drugs 0.000 claims abstract description 22
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 22
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 20
- 239000000378 calcium silicate Substances 0.000 claims abstract description 20
- 229910052918 calcium silicate Inorganic materials 0.000 claims abstract description 20
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 18
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000000126 substance Substances 0.000 claims abstract description 8
- 235000013350 formula milk Nutrition 0.000 claims description 13
- 235000020610 powder formula Nutrition 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000009461 vacuum packaging Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 6
- 239000011575 calcium Substances 0.000 abstract description 6
- 229910052791 calcium Inorganic materials 0.000 abstract description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 4
- 239000008101 lactose Substances 0.000 abstract description 4
- 235000013336 milk Nutrition 0.000 abstract description 4
- 239000008267 milk Substances 0.000 abstract description 4
- 210000004080 milk Anatomy 0.000 abstract description 4
- 239000006041 probiotic Substances 0.000 abstract description 4
- 235000018291 probiotics Nutrition 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 235000013343 vitamin Nutrition 0.000 abstract description 4
- 239000011782 vitamin Substances 0.000 abstract description 4
- 229930003231 vitamin Natural products 0.000 abstract description 4
- 229940088594 vitamin Drugs 0.000 abstract description 4
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 3
- 108010063045 Lactoferrin Proteins 0.000 abstract description 3
- 102000010445 Lactoferrin Human genes 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 3
- 102000018358 immunoglobulin Human genes 0.000 abstract description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract description 3
- 229940078795 lactoferrin Drugs 0.000 abstract description 3
- 235000021242 lactoferrin Nutrition 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 2
- 230000006870 function Effects 0.000 description 19
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000020254 sheep milk Nutrition 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010071421 milk fat globule Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a formula of goat milk powder with an immunity enhancing function and a production process thereof, wherein the goat milk powder is prepared from the following raw materials in parts by weight: 12000-16000 g of goat milk powder, 2500-3500 g of lactitol, 1000-3000 g of inulin, 600-1000 g of galacto-oligosaccharide, 100-300 g of calcium silicate, 10-30 g of modified soybean phospholipid, 10-30 g of lactobacillus acidophilus freeze-dried powder and 10-30 g of bifidobacterium animalis freeze-dried powder; the invention takes the goat milk powder as the main raw material, and adds lactitol, inulin, galacto-oligosaccharide, calcium silicate, modified soybean lecithin, lactobacillus acidophilus freeze-dried powder and bifidobacterium animalis freeze-dried powder in a matching way, so that the prepared goat milk powder is rich in natural nutrient substances such as protein, lactose, milk calcium, lactoferrin, immunoglobulin, amino acid, vitamin, probiotics and the like, has the biological effects of enhancing the human body immunity function and delaying senility, and has extremely high health-care effect.
Description
Technical Field
The invention relates to the technical field of milk powder formulas, in particular to a formula of goat milk powder with an immune enhancing function and a production process thereof.
Background
The goat milk is rich in high-quality protein such as albumin, globulin, etc., fatty acid and various mineral substances which have important effects on human health, and has good health care and treatment effects on patients with malabsorption syndrome. The goat milk fat globule is small (only 1/3 of cow milk), is rich in medium-chain and short-chain unsaturated fatty acids beneficial for direct utilization of organisms, and has high absorption rate. In addition, the abundant calcium element in the goat milk product can help human body burn fat and promote the organism to generate enzyme for degrading fat. The research shows that the calcium content of the goat milk is 15 percent higher than that of the cow milk and 5 times higher than that of the human milk. The goat milk is rich in superoxide dismutase, has skin caring effect, and has antiallergic effect. EGF (epidermal growth factor) contained in the goat milk has a repairing effect on mucosal epithelial cells such as intestines, stomach, trachea, skin and the like while promoting the growth of the epithelial cells, can promote digestion and calm the nerves (due to the cyclic nucleotide contained), can enhance the immunity of the organism, adjust the nutrition balance of the human body and improve the sleep quality, has an effect of promoting recovery on diseases such as nephritis, tuberculosis, asthma and the like due to the alkaline good buffer characteristic, and is a superior health care product for infants, pregnant women, the old and patients; however, long-term research shows that the existing formula goat milk powder has difficulty in realizing the effect of enhancing the immunity of the human body.
Therefore, the design of the goat milk powder formula with the function of enhancing the immunity has important significance.
Disclosure of Invention
In order to solve the problems, the invention provides a formula of goat milk powder with an immunity enhancing function and a production process thereof, so as to more exactly solve the problems in the background art.
The invention is realized by the following technical scheme: the formula of the goat milk powder with the function of enhancing the immunity is prepared from the following raw materials in parts by weight: 12000-16000 g of goat milk powder, 2500-3500 g of lactitol, 1000-3000 g of inulin, 600-1000 g of galacto-oligosaccharide, 100-300 g of calcium silicate, 10-30 g of modified soybean phospholipid, 10-30 g of lactobacillus acidophilus freeze-dried powder and 10-30 g of bifidobacterium animalis freeze-dried powder.
Preferably, the goat milk powder is prepared from the following raw materials in parts by weight: 12000g of goat milk powder, 2500g of lactitol, 1000g of inulin, 600g of galactooligosaccharide, 100g of calcium silicate, 10g of modified soybean phospholipid, 10g of lactobacillus acidophilus freeze-dried powder and 10g of bifidobacterium animalis freeze-dried powder.
Preferably, the goat milk powder is prepared from the following raw materials in parts by weight: 14000g of goat milk powder, 2940g of lactitol, 2000g of inulin, 800g of galacto-oligosaccharide, 200g of calcium silicate, 20g of modified soybean lecithin, 20g of lactobacillus acidophilus freeze-dried powder and 20g of bifidobacterium animalis freeze-dried powder.
Preferably, the goat milk powder is prepared from the following raw materials in parts by weight: 16000g of goat milk powder, 3500g of lactitol, 3000g of inulin, 1000g of galacto-oligosaccharide, 300g of calcium silicate, 30g of modified soybean phospholipid, 30g of lactobacillus acidophilus freeze-dried powder and 30g of bifidobacterium animalis freeze-dried powder.
A production process of goat milk powder with an immunity enhancing function is applied to the preparation of the goat milk powder formula with the immunity enhancing function, and comprises the following steps:
s1: adding goat milk powder, inulin, galacto-oligosaccharide, calcium silicate, modified soybean phospholipid, lactobacillus acidophilus freeze-dried powder and bifidobacterium animalis freeze-dried powder into a mixing stirrer, and uniformly stirring to obtain a goat milk solution;
s2: heating the goat milk solution to 50-60 ℃, and homogenizing under 10-15 MPa;
s3: keeping the temperature of the homogenized goat milk solution at 90-95 ℃ for 15-20 minutes for sterilization, and cooling to 40-45 ℃;
s4: and (4) carrying out spray drying on the sterilized goat milk solution to obtain a powdery substance, and carrying out vacuum packaging to obtain the goat milk powder finished product.
The invention has the beneficial effects that:
the invention provides a formula of goat milk powder with immunity enhancing function and a production process thereof, wherein goat milk powder is used as a main raw material, and lactitol, inulin, galacto-oligosaccharide, calcium silicate, modified soybean phospholipid, lactobacillus acidophilus freeze-dried powder and animal bifidobacterium freeze-dried powder are added, so that the prepared goat milk powder is rich in natural nutrient substances such as protein, lactose, milk calcium, lactoferrin, immunoglobulin, amino acid, vitamin, probiotics and the like, has biological effects of enhancing human immunity and delaying aging, and has extremely high health care effect.
Detailed Description
In order to more clearly and completely illustrate the technical solution of the present invention, the present invention is further described below.
Example 1:
the formula of the goat milk powder with the function of enhancing immunity is prepared from the following raw materials in parts by weight: 12000g of goat milk powder, 2500g of lactitol, 1000g of inulin, 600g of galactooligosaccharide, 100g of calcium silicate, 10g of modified soybean phospholipid, 10g of lactobacillus acidophilus freeze-dried powder and 10g of bifidobacterium animalis freeze-dried powder.
The production process of the goat milk powder with the immune enhancing function, which is applied to the preparation of the goat milk powder formula with the immune enhancing function, comprises the following steps:
s1: adding goat milk powder, inulin, galacto-oligosaccharide, calcium silicate, modified soybean phospholipid, lactobacillus acidophilus freeze-dried powder and bifidobacterium animalis freeze-dried powder into a mixing stirrer, and uniformly stirring to obtain a goat milk solution;
s2: heating the goat milk solution to 50 ℃, and homogenizing under 10 MPa;
s3: keeping the homogenized goat milk solution at 90 ℃ for 15 minutes for sterilization, and cooling to 40 ℃;
s4: and (4) carrying out spray drying on the sterilized goat milk solution to obtain a powdery substance, and carrying out vacuum packaging to obtain the goat milk powder finished product.
Example 2:
the formula of the goat milk powder with the function of enhancing immunity is prepared from the following raw materials in parts by weight according to the optimal ratio: 14000g of goat milk powder, 2940g of lactitol, 2000g of inulin, 800g of galacto-oligosaccharide, 200g of calcium silicate, 20g of modified soybean lecithin, 20g of lactobacillus acidophilus freeze-dried powder and 20g of bifidobacterium animalis freeze-dried powder.
The production process of the goat milk powder with the immune enhancing function, which is applied to the preparation of the goat milk powder formula with the immune enhancing function, comprises the following steps:
s1: adding goat milk powder, inulin, galacto-oligosaccharide, calcium silicate, modified soybean phospholipid, lactobacillus acidophilus freeze-dried powder and bifidobacterium animalis freeze-dried powder into a mixing stirrer, and uniformly stirring to obtain a goat milk solution;
s2: heating the goat milk solution to 55 ℃, and homogenizing under 15 MPa;
s3: keeping the homogenized goat milk solution at 95 ℃ for 20 minutes for sterilization, and cooling to 45 ℃;
s4: and (4) carrying out spray drying on the sterilized goat milk solution to obtain a powdery substance, and carrying out vacuum packaging to obtain the goat milk powder finished product.
Example 3:
the formula of the goat milk powder with the function of enhancing immunity is prepared from the following raw materials in parts by weight: 16000g of goat milk powder, 3500g of lactitol, 3000g of inulin, 1000g of galacto-oligosaccharide, 300g of calcium silicate, 30g of modified soybean phospholipid, 30g of lactobacillus acidophilus freeze-dried powder and 30g of bifidobacterium animalis freeze-dried powder.
The production process of the goat milk powder with the immune enhancing function, which is applied to the preparation of the goat milk powder formula with the immune enhancing function, comprises the following steps:
s1: adding goat milk powder, inulin, galactooligosaccharide, calcium silicate, modified soybean phospholipid, lactobacillus acidophilus freeze-dried powder and bifidobacterium animalis freeze-dried powder into a mixing stirrer, and stirring uniformly to obtain goat milk solution;
s2: heating the goat milk solution to 60 ℃, and homogenizing under 15 MPa;
s3: keeping the homogenized goat milk solution at 90 ℃ for 20 minutes for sterilization, and cooling to 40 ℃;
s4: and (4) carrying out spray drying on the sterilized goat milk solution to obtain a powdery substance, and carrying out vacuum packaging to obtain the goat milk powder finished product.
The above three groups of embodiments can be used as embodiments of the present invention, wherein embodiment 2 is the most preferred, the sheep milk powder formula with immunity enhancing function and the production process thereof provided by the present invention, the sheep milk powder is used as main raw material, and lactitol, inulin, galactooligosaccharide, calcium silicate, modified soybean phospholipid, lactobacillus acidophilus freeze-dried powder and animal bifidobacterium freeze-dried powder are added, so that the prepared sheep milk powder is rich in natural nutrients such as protein, lactose, milk calcium, lactoferrin, immunoglobulin, amino acids, vitamins, probiotics, etc., has biological effects of enhancing human body immunity and delaying aging, and has extremely high health care effect.
The efficacies of some components in the formula of the invention are as follows:
lactitol:
1. low heat: research shows that after human body ingests lactitol, the lactitol can not be detected in blood, only about 0.5 percent of the ingested amount in recovered urine is recovered, the amount in feces can be ignored, short-chain fatty acid and microorganisms in the feces are increased, so the lactitol is fermented and utilized by the microorganisms in large intestine, the released calorie is 8.36kJ/g, about half of sucrose, and the low-calorie sweetener belongs to. Thus, lactitol can be used alone or mixed with other sweeteners to replace sucrose to prepare low-calorie food, which meets the requirements of obese patients.
2. Edible sweetening agent for diabetic patients
Human body lacks beta-half lactase which decomposes lactitol, and the product cannot be detected in human blood after single administration of lactitol, so that lactitol cannot be digested and absorbed by intestines and stomach. The management of blood sugar is one of the main targets of the management of diabetic patients, and the intake of lactitol does not influence the blood sugar value and cause the increase of insulin, thereby meeting the special diet requirements of the diabetic patients, and being edible by both insulin-dependent (type I) and non-insulin-dependent (type II) diabetic patients.
3. Effect of lactitol on sucrose absorption
Lactitol has been shown to inhibit sucrose absorption, and lactitol and sucrose are present in a ratio of 1:1 ratio, the glucose content in the blood is half of that of the same amount of sucrose taken, and the liver glycogen formed is one fifth of that of the latter. Cholesterol-lowering serum cholesterol by 50% was achieved in mice fed daily cholesterol after lactitol was added to their diet.
4. Proliferating beneficial intestinal flora
When a human ingests 10g lactitol daily, fecal pH was significantly decreased after 7 days (P = 0.02), propionic and butyric acid concentrations were significantly increased (P = 0.001), bifidobacteria were significantly increased (P = 0.017), and there were few symptoms of gastrointestinal distress.
Inulin: inulin generally has the effects of clearing away heat and toxic materials, nourishing and protecting liver. The composition has the effects of enhancing gastrointestinal peristalsis, promoting in vivo waste toxin discharge, preventing constipation, regulating intestinal flora balance, and effectively reducing serum total cholesterol and low density lipoprotein cholesterol. Improving blood lipid, promoting absorption of trace elements such as calcium and magnesium, and enhancing immunity.
Galacto-oligosaccharide: the galacto-oligosaccharide is not only a water-soluble dietary fiber, but also a natural active substance, has a low heat value, can be well absorbed and utilized by intestinal tracts, cannot cause obesity, is not easily utilized by oral flora, and can also enhance the resistance of organisms.
Lactobacillus acidophilus freeze-dried powder:
1. can regulate flora balance in intestinal tract, and inhibit proliferation of undesirable microorganisms in intestinal tract.
2. The lactobacillus acidophilus and the bifidobacterium are mixed to form a leaven, and lactic acid and acetic acid are generated after fermentation in intestinal tracts, so that the utilization rate of calcium, phosphorus and iron can be improved, the absorption of iron and vitamins is promoted, vitamin K and vitamin B are generated, and the absorption of cholesterol can be reduced.
3. Has the functions of inhibiting the growth of harmful bacteria, promoting beneficial bacteria in intestinal tracts, killing harmful bacteria, regulating the imbalance of flora in vivo, reducing the generation of vivotoxin and relieving the detoxification burden of livers.
Animal bifidobacterium freeze-dried powder: has effects of relieving constipation and diarrhea. The bifidobacterium is a probiotic in human intestinal tracts, can decompose sugar into lactose and acetic acid, and change the microenvironment of the intestinal tracts, thereby promoting the peristalsis of the intestinal tracts and improving the constipation symptom. Also can inhibit the number of harmful bacteria, resist pathogenic bacteria infection, reduce toxin production, and protect liver function.
Of course, the present invention may have other embodiments, and based on the embodiments, other embodiments obtained by persons skilled in the art without any creative work are within the protection scope of the present invention.
Claims (5)
1. The formula of the goat milk powder with the function of enhancing immunity is characterized in that the goat milk powder is prepared from the following raw materials in parts by weight: 12000-16000 g of goat milk powder, 2500-3500 g of lactitol, 1000-3000 g of inulin, 600-1000 g of galacto-oligosaccharide, 100-300 g of calcium silicate, 10-30 g of modified soybean phospholipid, 10-30 g of lactobacillus acidophilus freeze-dried powder and 10-30 g of bifidobacterium animalis freeze-dried powder.
2. The formula of the goat milk powder with the function of enhancing immunity according to claim 1, wherein the goat milk powder is prepared from the following raw materials in parts by weight: 12000g of goat milk powder, 2500g of lactitol, 1000g of inulin, 600g of galacto-oligosaccharide, 100g of calcium silicate, 10g of modified soybean lecithin, 10g of lactobacillus acidophilus freeze-dried powder and 10g of bifidobacterium animalis freeze-dried powder.
3. The goat milk powder formula with the function of enhancing immunity according to claim 1, wherein the goat milk powder is prepared from the following raw materials in parts by weight: 14000g of goat milk powder, 2940g of lactitol, 2000g of inulin, 800g of galacto-oligosaccharide, 200g of calcium silicate, 20g of modified soybean lecithin, 20g of lactobacillus acidophilus freeze-dried powder and 20g of bifidobacterium animalis freeze-dried powder.
4. The formula of the goat milk powder with the function of enhancing immunity according to claim 1, wherein the goat milk powder is prepared from the following raw materials in parts by weight: 16000g of goat milk powder, 3500g of lactitol, 3000g of inulin, 1000g of galacto-oligosaccharide, 300g of calcium silicate, 30g of modified soybean phospholipid, 30g of lactobacillus acidophilus freeze-dried powder and 30g of bifidobacterium animalis freeze-dried powder.
5. A production process of goat milk powder with an immune enhancing function is applied to the preparation of the goat milk powder formula with an immune enhancing function in any one of claims 1 to 4, and is characterized by comprising the following steps:
s1: adding goat milk powder, inulin, galacto-oligosaccharide, calcium silicate, modified soybean phospholipid, lactobacillus acidophilus freeze-dried powder and bifidobacterium animalis freeze-dried powder into a mixing stirrer, and uniformly stirring to obtain a goat milk solution;
s2: heating the goat milk solution to 50-60 ℃, and homogenizing under 10-15 MPa;
s3: keeping the temperature of the homogenized goat milk solution at 90-95 ℃ for 15-20 minutes for sterilization, and cooling to 40-45 ℃;
s4: and (4) carrying out spray drying on the sterilized goat milk solution to obtain a powdery substance, and carrying out vacuum packaging to obtain the goat milk powder finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211394186.4A CN115918730A (en) | 2022-11-08 | 2022-11-08 | Formula and production process of goat milk powder with immunity enhancing function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211394186.4A CN115918730A (en) | 2022-11-08 | 2022-11-08 | Formula and production process of goat milk powder with immunity enhancing function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115918730A true CN115918730A (en) | 2023-04-07 |
Family
ID=86655127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211394186.4A Pending CN115918730A (en) | 2022-11-08 | 2022-11-08 | Formula and production process of goat milk powder with immunity enhancing function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115918730A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108935709A (en) * | 2018-07-16 | 2018-12-07 | 陕西科技大学 | A kind of probiotics goat milk piece and preparation method thereof |
| CN108935703A (en) * | 2018-07-16 | 2018-12-07 | 陕西科技大学 | A kind of compound probiotic goat milk powder and preparation method thereof |
-
2022
- 2022-11-08 CN CN202211394186.4A patent/CN115918730A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108935709A (en) * | 2018-07-16 | 2018-12-07 | 陕西科技大学 | A kind of probiotics goat milk piece and preparation method thereof |
| CN108935703A (en) * | 2018-07-16 | 2018-12-07 | 陕西科技大学 | A kind of compound probiotic goat milk powder and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 曾庆祝等: "《食品安全与卫生》", 31 October 2012, 中国质检出版社, pages: 239 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2552464B1 (en) | Use of bifidobacteria for preventing allergy in breastfed infants | |
| CN108812909B (en) | Complementary food nutritional supplement for improving monophagia or anorexia and preparation method thereof | |
| CN109430407A (en) | Probiotic combinations preparation | |
| CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
| CN111802550A (en) | Probiotic formula beverage and preparation method thereof | |
| JP4231208B2 (en) | Nutritional supplements derived from fermented milk for the prevention of osteoporosis | |
| CN112535218A (en) | Maternal emulsified infant formula milk powder for promoting intelligence development and intestinal health and preparation method and application thereof | |
| CN111903766A (en) | Infant formula milk powder and preparation method thereof | |
| CN113854360A (en) | Probiotic freeze-dried powder and preparation method thereof | |
| CN105815514A (en) | Weight-losing quinoa milk tea | |
| CN113693131A (en) | Probiotic selenium-rich high-calcium formula milk powder for middle-aged and elderly people | |
| TW201914432A (en) | Oligo-saccharide enhanced milk products having the functions of modulating blood lipid, improving intestinal flora and promoting immunity, and process for preparing the same | |
| CN102613289A (en) | Yogurt with low glycemic index | |
| CN112385843A (en) | Balanced nutrition powder containing composite prebiotics and preparation method thereof | |
| CN113876935A (en) | Composition for treating intestinal diseases of pets and application thereof | |
| CN112617083A (en) | Prebiotics solid beverage capable of relaxing bowel and reducing blood sugar and preparation method thereof | |
| KR102000170B1 (en) | Food compositions for reducing body fat and improving intestinal function | |
| CN102754695A (en) | Burdock probiotics goat milk slices and method for preparing same | |
| CN114794235B (en) | Chickpea polypeptide yoghurt and preparation method thereof | |
| CN115918730A (en) | Formula and production process of goat milk powder with immunity enhancing function | |
| JP3505043B2 (en) | Vitamin K supplements and foods for osteoporosis prevention and treatment | |
| CN108523136A (en) | A kind of composition containing lactase | |
| CN115702654A (en) | Middle-aged and old-aged modified goat milk powder assisting in reducing blood sugar and preparation method thereof | |
| CN110959797A (en) | Prebiotics soybean protein peptide solid beverage and preparation process thereof | |
| CN110169452A (en) | A kind of aid digestion Yoghourt and preparation method thereof containing converted starch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |